In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Florentina-Geanina LupascuDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0001-5569-1863 Gabriela-Dumitrița StanciuAdvanced Center for Research and Development in Experimental Medicine "Prof. Ostin C. Mungiu", Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0003-4440-9628 Bianca-Ștefania ProfireDepartment of Internal Medicine, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0003-1792-7139 Roxana-Georgiana TaușerDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0002-8965-4208 Dan LupașcuDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0002-3007-7311 Andreea-Teodora IacobDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0003-2530-3801 Ioana-Mirela VasincuDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0002-0873-2789 Maria ApotrosoaeiDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.
Alexandru SavaDepartment of Analytical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0002-2759-4860 Bogdan-Ionel TambaAdvanced Center for Research and Development in Experimental Medicine "Prof. Ostin C. Mungiu", Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0001-9868-1999 Lenuța ProfireDepartment of Pharmaceutical and Therapeutical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy Iasi, 16 Universitatii Street, 700115 Iasi, Romania.ORCID 0000-0002-7953-3023 Funding
grant of the Ministry of Education and Research, CCDI-UEFISCDI project number PN-IV-PCB-RO-MD-2024-0246, within PNCDI IV.Ministry of Education PN-III-P4-ID-PCE-2020-2687 (grant no. 244/2021))Romanian Ministry of Education and Research (CNCS-UEFISCDI PN-III-P4-ID-PCE-2020-2687 (grant no. 244/2021))
6 · The paper itselfAbstract
Diabetes mellitus (DM) is a highly prevalent metabolic disorder and a major public health concern. Pioglitazone, a widely used antidiabetic agent, exhibits limited therapeutic efficiency due to poor water solubility and suboptimal pharmacokinetic properties. Similarly, curcumin (Cur), a natural polyphenol with pleiotropic biological activities, is hindered by low oral bioavailability. In this study, chitosan-based nanocarriers were developed for the delivery of pioglitazone (CS-Pio NPs), curcumin (CS-Cur NPs), and their co-encapsulation (CS-Pio-Cur NPs), aiming to enhance their biological performance and therapeutic efficacy. The co-loaded nanosystem (CS-Pio-Cur NPs) demonstrated significantly enhanced antioxidant activity, as evidenced by DPPH (71.29 ± 0.09%), ABTS (86.08 ± 0.04%), and hydroxyl radical scavenging (87.08 ± 0.06%) assays, along with a strong reducing capacity (IC
Indexed as
ChitosanCurcuminDiabetes Mellitus, ExperimentalDrug CarriersHypoglycemic AgentsNanoparticlesPioglitazoneAnimalsAntioxidantsBlood GlucoseMaleRatsAntioxidantsBlood GlucoseChitosanCurcuminDrug CarriersHypoglycemic AgentsPioglitazoneantioxidant activityco-delivery nanocarrierscurcumindiabetes mellitus type 2lipidic profileliver toxicitypioglitazonepolymer nanoparticlerenal injury
Identifiers
PMID42450269
PMCPMC13360986
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390